INCPF innocare announces phase III study results of tyk2 inhibitor soficitinib meet primary endpoint in patients with atomic dermatitis Inno
INCPF innocare announces phase III study results of tyk2 inhibitor soficitinib meet primary endpoint in patients with atomic dermatitis Innocare Pharma - soficitinib shows good safety profile with no new safety signals - Soficitinib achieves statistically significant primary and multiple secondary endpoints
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.